Citrullination: The loss of tolerance and development of autoimmunity in rheumatoid arthritis

Reumatismo

Volumn 60, Issue 2, 2008, Pages 85-94

  Alivernini, S ^a   Fedele, A L ^a   Cuoghi, I ^a   Tolusso, B ^a   Ferracciolo, Gianfranco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anti citrullinated peptides antibodies; Autoimmunity; Citrulline; Loss of tolerance; Rheumatoid arthritis

Indexed keywords

ARGININE; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPITOPE; HLA ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN ARGININE DEIMINASE; RHEUMATOID FACTOR;

AMINO ACID SUBSTITUTION; AUTOIMMUNITY; CELLULAR DISTRIBUTION; CHROMOSOME 1P; CHRONIC INFLAMMATION; CIGARETTE SMOKING; EARLY DIAGNOSIS; GENE LINKAGE DISEQUILIBRIUM; GENETIC LINKAGE; HUMAN; INTERSTITIAL PNEUMONIA; NEGATIVE FEEDBACK; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYNOVIUM; GENETICS; IMMUNOLOGY; JOINT; METABOLISM;

ARGININE; ARTHRITIS, RHEUMATOID; CITRULLINE; HUMANS; JOINTS;

EID: 55249084235     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Fearon WR. The carbamido diacetyl reaction: A test for citrulline. Biochem J 1939; 33: 902-7.
2. van Venrooij WJ, Pruijn, GJ. Citrullination: A small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2000; 2: 249-51.
3. Tarcsa E, Marekov LN, Mei G, Melino G, Lee SC, Steinert PM. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 1996; 271: 30709-16.
4. Chavanas S, Mechin MC, Takahara H, Kawada A, Nachat R, Serre G, et al. Comparative analysis of the mouse and human peptidylarginine deiminase gene cluster reveals highly conserved non-coding segments and a new human gene, PADI6. Gene 2004; 330: 19-27.
5. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease. Bioessays 2003; 25: 1106-18.
6. Arita K, Hashimoto H, Shimizu T, Nakashima K, Yamada M, Sato M. Structural basis for Ca(2+)-induced activation of human PAD4. Nat Struct Mol Biol 2004; 11: 777-83.
7. Kubilus J, Baden HP. Purification and properties of a brain enzyme which deiminates proteins. Biochim Biophys Acta 1983; 745: 285-91.
8. Kubilus J, Waitkus RF, Baden HP. Partial purification and specificity of an arginine-converting enzyme from bovine epidermis. Biochim Biophys Acta 1980; 615: 246-51.
9. Raijmakers R, Zendman AJ, Egberts WV, Vossenaar ER, Raats J, Soede-Huijbregts C, et al. Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. J Mol Biol 2007; 367: 1118-29.
10. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, et al Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34: 395-402.
11. Mechin MC, Enji M., Nachat R, Chavanas S, Charveron, M, Ishida-Yamamoto A, et al. The peptidylarginine deiminases expressed in human epidermis differ in their substrate specificities and subcellular locations. Cell Mol Life Sci 2005; 62: 1984-95.
12. Takahara, H, Okamoto, H, Sugawara, K. Calciumdependent properties of peptidylarginine deiminase from rabbit skeletal muscle. Agric Biol Chem 1986; 50: 2899-904.
13. Senshu T, Akiyama K, Nagata S, Watanabe K, Hikichi K. Peptidylarginine deiminase in rat pituitary: Sex difference, estrous cycle-related changes, and oestrogen dependence. Endocrinology 1989; 124: 2666-70.
14. Takahara H, Kusubata M, Tsuchida M, Kohsaka T, Tagami S,Sugawara Expression of peptidylarginine deiminase in the uterine epithelial cells of mouse is dependent on oestrogen. J Biol Chem 1992; 267: 520-5.
15. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004; 4: 239-62.
16. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 1964; 23: 302-5.
17. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979; 2: 97-9.
18. Sebbag M, Simon M, Vincent C, Masson-Bessie're C, Girbal E, Durieux JJ, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995; 95: 2672-9.
19. Masson-Bessie're C, Sebbag M, Durieux JJ, Nogueira L, Vincent C, Girbal-Neuhauser E, et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 2000; 119: 544-52.
20. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BAW, van Venrooij WJ, et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 2001; 44: 41-7.
21. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002; 60: 383-8.
22. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-9.
23. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-6.
24. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-15.
25. Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D, et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 2004; 135: 173-80.
26. Soderlin MK, Kastbom A, Kautiainen H, Leirisalo-Repo M, Strandberg G, Skogh T. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol 2004; 33: 185-8.
27. Chapuy Regaud S, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T et al. Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitidies. J Immunol 2005; 174: 507-64.
28. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T et al. The mayor synovial targets of the rheumatoid arthritis-specific antifilagrin autoantibodies are determinated forms of the alpha and beta chains of fibrin. J Immunol 2001; 166: 417-84.
29. Sanchez-Pernaute O, Largo R, Calvo E, Alvarez-Soria MA, Egido J, Herrero-Beaumont G. A fibrin based model for rheumatoid synovitis. Ann Rheum Dis 2003; 62: 1135-8.
30. Scott JP, Gerber P, Maryjowski MC, Pachman LM. Evidence for intravascular coagulation in systemic onset, but not polyarticular, juvenile rheumatoid arthritis. Arthritis Rheum 1985; 28: 256-61.
31. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology (Oxford) 2005; 44: 1374-82.
32. Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994; 21: 1027-33.
33. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6: R142-50.
34. Nakashima K, Hagiwara T, Yamada M. Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J Biol Chem 2002; 277: 49562-8.
35. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L, et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004; 306: 279-83.
36. Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S., Tokuhiro S et al. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis Rheumatology 2005; 44: 40-50.
37. Cornelis F, Fauré S, Martinez M, Prud'homme JF, Fritz P, Dib C, et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci USA 1998; 95: 10746-50.
38. Shiozawa S, Hayashi S, Tsukamoto Y, Goko H, Kawasaki H, Wada T, et al. Identi.cation of the gene loci that predispose to rheumatoid arthritis. Int Immunol 1998; 10: 1891-5.
39. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34: 395-402.
40. Skriner K, Adolph K, Jungblut PR, Burmester GR. Association of citrullinated proteins with synovial exosoes. Athritis Rheum. 2006; 12: 3809-14.
41. Thery C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3: 1156-62.
42. Distler JH, Jüngel A, Huber LC, Seemayer CA, Reich CF 3rd, Gay RE, et al. The induction of matrix metalloproteinase and cytokines expression in synovial fibroblasts stimulated with immune cells microparticles. Proc Natl Acad Sci USA 2005; 102: 2892-7.
43. Bence Gyorgy, Erzsébet Tòth, Edit Tarcsa, Andràs Falus, Edit I. Buzàs Citrullination: A posttranslational modification in health and disease The International Journal of Biochemistry & Cell Biology 2006; 38: 1662-7.
44. Makrygiannakis D, Lundberg K, Ulfgren AK, Klareskog L, Catrina A. Citrullination is an inflammation dependent process. Ann Rheum Dis 2006; 65 Suppl 1: A24.
45. Bongartz T, Cataert T, Atkins SR, Harle P, Myers JL, Turesson C et al Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology 2007; 46: 70-5.
46. Fery H, Jones M, Vaux DJ, Roberts IS, Cornall RJ. The cellular location of self antigen determines the positive and negative selection of autoreactive B cells. J Exp Md 2003; 198: 1415-25.
47. Erik R Vossenaar, Albert JW Zendman and Walther J van Venrooij Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis Arthritis Res Ther 2004; 6:1-5
48. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85: 307-10.
49. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 269-81.
50. Zanelli E, Breedveld FC, de Vries RR. HLA class II association with rheumatoid arthritis: facts and interpretations. Hum Immunol 2000; 61: 1254-61.
51. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC: X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997; 7: 473-81.
52. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004; 50: 2113-21.
53. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831-5.
54. De Vries RRp, Huizinga TW, Toes RE. HLA and RA revisited: citrullinated food for the SE hypothesis, the DR6 effect and NIMA. J Immunol 2006; 67: 454-9.
55. Stuehr DJ. Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol 1997; 37: 339-59.
56. Bogdan C. nitric oxide and the immune response. Nat Immunol 2001; 2: 907-16.
57. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu S Interferon production by antigen presenting cells: mechanisms emerge. Trends Immunol 2001; 22: 556-60.
58. Werner-Felmayer G, Golderer G, Werner ER. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr. Drug Metabol 2002; 3: 159-73.
59. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992; 6: 3051-64.
60. Kolb H, Kolb-Bachofen V. Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator. Immunol Today 1998; 19: 556-61.
61. Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001; 2: 907-16.
62. Bogdan C. The multiplex function of nitric oxide in (auto)immunity. J Exp Med 1998; 187: 1361-5.
63. Gilkeson, GS, Mudgett JS, Seldin MF, Ruiz P, Alexander AA, Misukonis MA et al. Clinical and serologic manifestations of autoimmune disease in MRL-1pr/1pr mice lacking nitric oxide synthase type 2. J Exp Med 1997; 186: 365-373.
64. McCartney-Francis N L, Song XY, Mizel DE, Wahl, S M. Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease. J Immunol 2001; 166: 2734-40.
65. Ling S, Lai A, Borschukova O, Pumpens P, Holoshitz J. Activation of nitric oxide signalling by the rheumatoid arthritis shared epitope. Arthritis Rheum 2006; 54: 3423-32.
66. Hazes JM, Dijkmans BA, Vandenbroucke JP, de Vries RR, Cats A. Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption. Ann Rheum Dis 1990; 49: 980-2.
67. Heliovaara M, Aho K, Aromaa A, Knekt P, Reunanen A. Smoking and risk of rheumatoid arthritis. J Rheumatol 1993; 20: 1830-5.
68. Krishnan E, Sokka T, Hannonen P. Smoking-gender interaction and risk for rheumatoid arthritis. Arthritis Res Ther 2003; 5: R158-62.
69. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003; 62: 835-41.
70. Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997; 40: 1955-61.
71. Uhlig T, Hagen KB, Kvien TK. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol 1999; 26: 47-54.
72. Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 1994; 5: 525-32.
73. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006; 8: R133.
74. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004; 50: 3085-92.
75. Mattey DL, Dawes PT, Clarke S, Fisher J, Brownfield A, Thomson W et al. Relationship among the HLA-DRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis. Arthritis Rheum 2002; 47: 403-7.
76. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope) - restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
77. Hye-Soon Lee, Irigoyen P, Kern M, Lee A, Batliwalla F, Khalili H, et al. Interaction Between Smoking, the Shared Epitope, and Anti-Cyclic Citrullinated Peptide A Mixed Picture in Three Large North American Rheumatoid Arthritis Cohorts Arthritis Rheum 2007; 56: 1745-53.
78. Michou L, Teixeira VH, Pierlot C, Lasbleiz S, Bardin T, Dieudé P, et al Associations between genetic factors, tobacco smoking and autoantibodies in familial and sporadic rheumatoid arthritis. Ann Rheum Dis 2008; 67: 466-70.